Page last updated: 2024-12-08
3,5-dihydroxyphenylpropionic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3,5-dihydroxyphenylpropionic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 161525 |
| CHEBI ID | 189725 |
| SCHEMBL ID | 490382 |
| MeSH ID | M0041022 |
Synonyms (23)
| Synonym |
|---|
| 3,5-dihydroxyphenylpropionic acid |
| benzenepropanoic acid, 3,5-dihydroxy- |
| 3-(3,5-dihydroxyphenyl)propionic acid |
| CHEBI:189725 |
| 3-(3,5-dihydroxyphenyl)propanoic acid |
| 26539-01-5 |
| unii-7yu8r3vq5r |
| 7yu8r3vq5r , |
| 3,5-dihydroxybenzenepropanoic acid |
| 3-(3,5-dihydroxyphenyl)-1-propanoic acid |
| 3,5-dihydroxyhydrocinnamic acid |
| benzenepropanoic acid,3,5-dihydroxy- |
| SCHEMBL490382 |
| DTXSID90181110 |
| 3,5-dihydroxyhydrocinnamic acid, analytical standard |
| AKOS030240034 |
| Q15410158 |
| 3,5-dihydroxyphenylpropionoic acid |
| SY266809 |
| mfcd12923243 |
| 35-dihydroxyhydrocinnamic acid_35-dihydroxyphenylpropionic acid |
| hydrocinnamic acid, 3,5-dihydroxy- |
| 3-(3,5-dihydroxyphenyl)propanoicacid |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " In the pharmacokinetic study, a group of 12 volunteers consumed a polyphenolic-restricted diet for 4 d before ingesting WG wheat bread containing 61 mg of alkylresorcinols." | ( Identification and pharmacokinetics of novel alkylresorcinol metabolites in human urine, new candidate biomarkers for whole-grain wheat and rye intake. Chen, X; Sang, S; Shurlknight, KL; Zhu, Y, 2014) | 0.4 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " This dose-response relationship was independent of age, sex, energy intake, and baseline urinary AR metabolite concentration." | ( Comparison of plasma alkylresorcinols (AR) and urinary AR metabolites as biomarkers of compliance in a short-term, whole-grain intervention study. Blumberg, JB; Chen, CY; Jacques, PF; Lichtenstein, AH; Livingston, KA; Ma, J; Marklund, M; McKeown, NM; Rasmussen, HM; Ross, AB, 2016) | 0.43 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| monocarboxylic acid | An oxoacid containing a single carboxy group. |
| benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||